Tharimmune rises after naming new chairman, COO

Canton Strategic Holdings

06/02/2026 13:30

** Shares of drug-developer Tharimmune THAR.O rise 7.9% to $4.24 premarket

**  Co says CEO Mark Wendland becomes chairman, replacing Vincent LoPriore, who stays on the board

**  Co says it hired Angela Radkowski as COO, joining from trading firm DRW; previously worked at Citadel

**  Leadership moves aimed at expanding co's digital‑asset platform and work on the Canton Network, Wendland says

** Shares up ~29% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))